Dechra launches new strangles toolkit for veterinary practices - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Dechra launches new strangles toolkit for veterinary practices

Dechra has launched a new strangles toolkit to support veterinary practices in advising and educating their clients on strangles and the important role of vaccination

Dechra Veterinary Products has launched a new strangles toolkit to support veterinary practices wanting to talk to their clients about this important disease and how to help control it with vaccinations.

The toolkit is designed to support the company’s innovative protein-based strangles vaccine for horses and ponies, Strangvac. It will help veterinary professionals advise and educate their clients on strangles and the important role of vaccination alongside good stable management and biosecurity procedures in improving herd immunity and thereby reducing the number of cases in the equine population.

The pack contains:

  • Ready-to-use social media posts for Facebook and Twitter ensuring that vet practices can create compelling and eye-catching content for their clients
  • Practice newsletter and website content
  • Videos on strangles pathogenesis and biosecurity
  • Client evening invitations
  • Strangles VetEq note featuring comprehensive information on strangles
  • Images of horses with strangles abscesses
  • Link to the Decha strangles therapy area webpage

All the resources are in an easy-to-use format and are interchangeable. For example, the social media posts can be linked to strangles content on a practice website or, alternatively, through to Dechra’s website.

Strangvac is the first and only intramuscular vaccine to help protect against strangles. It contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and features DIVA (Differentiating Infected from Vaccinated Animals) capability. The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests, a key feature in outbreak management. The proteins used in Strangvac are not the same as those used for iELISA testing methods and therefore animals will not test positive via blood test.

Trials demonstrate that Strangvac can protect more than 94 percent of horses, reducing the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses. 

It can be given to foals from five months of age and two injections should be given at a four-week interval. Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months. Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.

For further information on the strangles practice toolkit or the Strangvac vaccine please contact your local Dechra equine sales manager.

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more